Heron Therapeutics: Corporate Presentation (Heron Therapeutics) - Feb 14, 2016 - "STUDYC2006; SUSTOL was non-inferior to IV palonosetron in preventing acute and delayed CINV in MEC and acute CINV in HEC"; "Although not statistically significant, there was a trend favoring SUSTOL vs. palo in preventing delayed CINV in HEC, signaling an opportunity that led to the MAGIC study"; "Because the study was designed to show non-inferiority, P=NS indicates that the endpoint of non-inferiority was reached, and that SUSTOL was effective as IV palonosetron"
P3 data • Oncology
|